255 related articles for article (PubMed ID: 33864237)
21. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
22. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].
Gerhartz HH; Thiel E; Hiller E; Nerl C; Wilmanns W; Huhn D
Dtsch Med Wochenschr; 1986 Oct; 111(40):1511-5. PubMed ID: 2428572
[TBL] [Abstract][Full Text] [Related]
26. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.
Kagami Y; Itoh K; Tobinai K; Fukuda H; Mukai K; Chou T; Mikuni C; Kinoshita T; Fukushima N; Kiyama Y; Suzuki T; Sasaki T; Watanabe Y; Tsukasaki K; Hotta T; Shimoyama M; Ogura M;
Int J Hematol; 2012 Jul; 96(1):74-83. PubMed ID: 22661011
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
[TBL] [Abstract][Full Text] [Related]
30. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
[No Abstract] [Full Text] [Related]
32. Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Kasahara S; Goto H; Fukuno K; Yamada T; Sawada M; Yasuda I; Katsumura N; Takahashi T; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2010 Jan; 136(1):65-70. PubMed ID: 19590893
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
[TBL] [Abstract][Full Text] [Related]
34. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Camus V; Thieblemont C; Gaulard P; Cheminant M; Casasnovas RO; Ysebaert L; Damaj GL; Guidez S; Pica GM; Kim WS; Lim ST; Andre M; Gutiérrez N; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Tucci A; Fogarty P; Farhat H; Abraham J; Abarah W; Belmecheri F; Ribrag V; Delfau-Larue MH; Cottereau AS; Itti E; Li J; Delarue R; de Leval L; Morschhauser F; Bachy E
J Clin Oncol; 2024 May; 42(14):1612-1618. PubMed ID: 38364196
[No Abstract] [Full Text] [Related]
35. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
36. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
37. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
38. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen.
Chen XG; Huang H; Tian Y; Guo CC; Liang CY; Gong YL; Zou BY; Cai RQ; Lin TY
Chin J Cancer; 2011 Oct; 30(10):731-8. PubMed ID: 21959050
[TBL] [Abstract][Full Text] [Related]
40. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
